drugset / Trial / NCT03074591
Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction
RandomizedParallel-groupDouble-blindTreatment
Summary
This study addresses, whether treatment with IV iron for patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency (ID), both with or without anaemia, can improve exercise capacity as measured by 6-minute walking test (6-MWT) and symptoms while being safe
Timeline
- Start
- 2017-08-01
- Primary completion
- 2022-12-13
- Completion
- 2024-04-10
Publications
- Background von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Diek M, Karakas M, Birkemeyer R, Fillippatos G, Ponikowski P, Böhm M, Friede T, Anker SD. Iron deficiency in heart failure with preserved ejecton fracton: ratonale and design of the FAIR-HFpEF trial. Global Cardiol 2023; 1: 39-46.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ferric carboxymaltose | Other / unclassified | 50 mg/ml | Intravenous |